The adjunctive use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) as an addition to insulin is increasingly viewed as a method for addressing the rising prevalence of obesity in type 1 diabetes (T1D). Current GLP-1 RA drugs, such as semaglutide and the dual glucagon-insulinotropic peptide (GIP)/GLP-1 tirzepatide...
https://launchlinks.com/jacemembers
.png)
7200 Powers Ave. #151 Jacksonville, Florida 32217
19047291091
jtparish02@outlook.com
Copyright © 2023 jacenews24. All Rights Reserved
